United Therapeutics insider sales: 4,000 shares planned; 40,000 sold recently

Rhea-AI Filing Summary

United Therapeutics (UTHR) Form 144 notice: The filer disclosed a proposed sale of 4,000 common shares to be executed on 09/22/2025 through TD Securities (USA) LLC, with an aggregate market value of $1,669,212.50. The filing shows 45,230,000 shares outstanding. Acquisition details state the shares were originally acquired on 03/15/2016 as part of executive deferred compensation from Martine Rothblatt, totaling 294,000 shares under that grant and paid via exercised vested options. The filing also lists nine sales by Martine Rothblatt from 09/09/2025 to 09/19/2025 totaling 40,000 shares, with per-day gross proceeds reported for each sale.

Positive

• Clear Rule 144 disclosure identifying broker, date, share count, and aggregate market value
• Detailed list of recent sales (nine sales from 09/09/2025 to 09/19/2025) with per-sale gross proceeds

Negative

• Significant insider sales recorded (totaling 40,000 shares over nine trades), which may be viewed unfavorably by some investors
• No operational or financial data included to provide context for the sales or the issuer’s current performance

Insights

Corporate Governance Expert

TL;DR: The filing documents scheduled insider sales and recent daily disposals by a named executive, showing transparency but no new corporate actions.

The Form 144 is a routine disclosure of proposed insider sales under Rule 144. It identifies the broker, specific share counts, acquisition origin (executive deferred compensation on 03/15/2016), and an upcoming sale date of 09/22/2025. The filing also records nine recent sales between 09/09/2025 and 09/19/2025 aggregating 40,000 shares with daily gross proceeds reported. From a governance perspective, the document fulfils disclosure obligations; it does not state any material corporate developments, plan adoptions, or undisclosed material information.

Securities Analyst

TL;DR: Insider liquidity events are visible via detailed sale dates and proceeds; no earnings or operational metrics included.

The filing provides precise transactional detail useful for monitoring insider supply: a proposed 4,000-share sale valued at $1.67M and documented prior sales totaling 40,000 shares with listed gross proceeds by date. It clarifies the securities’ origin as executive deferred compensation tied to vested options from 2016 (294,000 shares referenced). There is no financial performance data, guidance, or statements about intent beyond the sales themselves, limiting valuation implications to observable insider disposals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1669212.50	45230000	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does United Therapeutics (UTHR) disclose in this Form 144?

The filing discloses a proposed sale of 4,000 common shares scheduled for 09/22/2025 via TD Securities (USA) LLC, with an aggregate market value of $1,669,212.50.

Who is the person selling shares in this filing for UTHR?

The filing identifies Martine Rothblatt as the person associated with the securities to be sold and lists prior sales in her name.

How many shares were sold recently by the insider and when?

The filing lists nine sales from 09/09/2025 to 09/19/2025 totaling 40,000 shares, with gross proceeds reported for each sale date.

How were the shares originally acquired according to the Form 144?

The shares were acquired on 03/15/2016 as executive deferred compensation from Martine Rothblatt, with 294,000 shares noted under that acquisition entry.

What exchange will the proposed sale occur on?

The proposed sale is listed to occur on NASDAQ through TD Securities (USA) LLC.